Regeneron Pharmaceuticals sees strength in Dupixent, oncology gains, and major buybacks despite setbacks. Find out why REGN ...

Boston conference will explore strategic partnering, device innovation, and delivery solutions for emerging therapeutics.

Analysts have recently evaluated Regeneron Pharmaceuticals and provided 12-month price targets. The average target is $769.35, accompanied by a high estimate of $975.00 and a low estimate of $547.00.

Sanofi and Regeneron Pharmaceuticals said they got Food and Drug Administration approval for anti-inflammatory drug Dupixent as a treatment for a rare skin disease, adding an eighth indication in ...

Per the deal, Thermo Fisher will acquire Sanofi’s sterile drug product manufacturing facility in Ridgefield, NJ, to support ...

For the second time this year, Leo Pharma has struck a partnership with a major drugmaker, this time paying Boehringer ...

Learn about June 2025’s top biotech deals, featuring major collaborations in small molecules, protein therapeutics, and ...

Detailed price information for Teva Pharmaceutical Industries ADR (TEVA-N) from The Globe and Mail including charting and ...

Sanofi’s SNY stock has been trading below its 200-day and 50-day moving averages since early June. On June 23, the stock’s closing price of $48.18 was below its 50-day moving average of $50.32 and the ...

Under the expanded partnership, Thermo Fisher will acquire Sanofi's sterile fill-finish and packaging facility in Ridgefield, N.J. The science-services and instruments provider said Wednesday that it ...

Thermo Fisher Scientific Inc. has expanded its strategic partnership with Sanofi to enable additional U.S. drug product manufacturing.